Literature DB >> 29428449

PD-1 /PD-L1 checkpoint in hematological malignancies.

O Annibali1, A Crescenzi2, V Tomarchio3, A Pagano3, A Bianchi2, A Grifoni4, G Avvisati3.   

Abstract

Programmed cell death protein 1 (PD-1), is a cell surface receptor with an important role in down-regulating the immune system and promoting self-tolerance by suppressing T cell inflammatory activity. PD-1/PDL1 axis represents a checkpoint to control immune responses and it is often used as a mechanism of immune escaping by cancers and infectious diseases. Many data demonstrate its important role in solid tumors and report emerging evidences in lymphoproliferative disorders. In this review, we summarized the available data on the role of PD-1/PD-L1 checkpoint in lymphoproliferative diseases and the therapeutics use of monoclonal blocking antibodies.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Immunotherapy; Lymphoproliferative disorders; PD-1; PD-1/PD-L1 checkpoint; PD-L1

Mesh:

Substances:

Year:  2018        PMID: 29428449     DOI: 10.1016/j.leukres.2018.01.014

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  13 in total

1.  PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-AKT signaling pathway.

Authors:  Fang Wang; Liqiong Yang; Mintao Xiao; Zhuo Zhang; Jing Shen; Songyot Anuchapreeda; Singkome Tima; Sawitree Chiampanichayakul; Zhangang Xiao
Journal:  Sci Rep       Date:  2022-07-06       Impact factor: 4.996

Review 2.  Targeting SHP2 phosphatase in hematological malignancies.

Authors:  Rahul Kanumuri; Santhosh Kumar Pasupuleti; Sarah S Burns; Baskar Ramdas; Reuben Kapur
Journal:  Expert Opin Ther Targets       Date:  2022-05-03       Impact factor: 6.797

Review 3.  Targeting autophagy in liver cancer.

Authors:  Pietro Di Fazio; Sami Matrood
Journal:  Transl Gastroenterol Hepatol       Date:  2018-07-10

Review 4.  Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies.

Authors:  Alejandro Olivares-Hernández; Luis Figuero-Pérez; Eduardo Terán-Brage; Álvaro López-Gutiérrez; Álvaro Tamayo Velasco; Rogelio González Sarmiento; Juan Jesús Cruz-Hernández; José Pablo Miramontes-González
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.241

5.  CAR-T 19 combined with reduced-dose PD-1 blockade therapy for treatment of refractory follicular lymphoma: A case report.

Authors:  Jia Wang; Qi Deng; Yan-Yu Jiang; Rui Zhang; Hai-Bo Zhu; Juan-Xia Meng; Yu-Ming Li
Journal:  Oncol Lett       Date:  2019-08-27       Impact factor: 2.967

6.  The Important Role of Immunotherapies in Acute Myeloid Leukemia.

Authors:  Jochen Greiner
Journal:  J Clin Med       Date:  2019-11-22       Impact factor: 4.241

7.  A novel scoring system for TIGIT expression in classic Hodgkin lymphoma.

Authors:  Ombretta Annibali; Antonella Bianchi; Alba Grifoni; Valeria Tomarchio; Mariantonietta Tafuri; Martina Verri; Giuseppe Avvisati; Anna Crescenzi
Journal:  Sci Rep       Date:  2021-03-29       Impact factor: 4.379

Review 8.  Immune checkpoint inhibitors in lymphoma: challenges and opportunities.

Authors:  Haris Hatic; Devi Sampat; Gaurav Goyal
Journal:  Ann Transl Med       Date:  2021-06

9.  In tumor cells, thyroid hormone analogues non-immunologically regulate PD-L1 and PD-1 accumulation that is anti-apoptotic.

Authors:  Hung-Yun Lin; Yu-Tang Chin; Ya-Jung Shih; Yi-Ru Chen; Matthew Leinung; Kelly A Keating; Shaker A Mousa; Paul J Davis
Journal:  Oncotarget       Date:  2018-09-25

10.  Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma.

Authors:  Yanjie Zhao; Feng Shi; Quan Zhou; Yuchen Li; Jiangping Wu; Ruibin Wang; Qingkun Song
Journal:  Medicine (Baltimore)       Date:  2020-11-06       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.